These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25793663)

  • 1. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
    Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
    Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis.
    Tan Y; Sementino E; Liu Z; Cai KQ; Testa JR
    Sci Rep; 2020 Sep; 10(1):15837. PubMed ID: 32985581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.
    Xu J; Testa JR
    J Biol Chem; 2009 Jul; 284(31):20593-601. PubMed ID: 19497851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.
    Tan Y; Sementino E; Xu J; Pei J; Liu Z; Ito TK; Cai KQ; Peri S; Klein-Szanto AJ; Wiest DL; Testa JR
    Oncotarget; 2017 Feb; 8(9):14941-14956. PubMed ID: 28122332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.
    Tan Y; Timakhov RA; Rao M; Altomare DA; Xu J; Liu Z; Gao Q; Jhanwar SC; Di Cristofano A; Wiest DL; Knepper JE; Testa JR
    Cancer Res; 2008 Mar; 68(5):1296-302. PubMed ID: 18316591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
    Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
    Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
    Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
    Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.
    Timakhov RA; Tan Y; Rao M; Liu Z; Altomare DA; Pei J; Wiest DL; Favorova OO; Knepper JE; Testa JR
    Genes Chromosomes Cancer; 2009 Sep; 48(9):786-94. PubMed ID: 19530243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
    Reynolds C; Roderick JE; LaBelle JL; Bird G; Mathieu R; Bodaar K; Colon D; Pyati U; Stevenson KE; Qi J; Harris M; Silverman LB; Sallan SE; Bradner JE; Neuberg DS; Look AT; Walensky LD; Kelliher MA; Gutierrez A
    Leukemia; 2014 Sep; 28(9):1819-27. PubMed ID: 24552990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.